Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sanofi-Aventis S.A. (SNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 105,114,056
  • Shares Outstanding, K 2,508,090
  • Annual Sales, $ 40,921 M
  • Annual Income, $ 4,285 M
  • 36-Month Beta 0.83
  • Price/Sales 2.65
  • Price/Cash Flow 8.78
  • Price/Book 1.60

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.97 +8.67%
on 06/21/18
42.61 -0.61%
on 07/06/18
+2.91 (+7.38%)
since 06/20/18
3-Month
37.43 +13.14%
on 05/09/18
42.61 -0.61%
on 07/06/18
+2.39 (+5.98%)
since 04/20/18
52-Week
37.43 +13.14%
on 05/09/18
50.65 -16.39%
on 09/22/17
-5.71 (-11.88%)
since 07/20/17

Most Recent Stories

More News
6 European Stocks to Shun on Tapered IMF Outlook

IMF lowered its growth projection for in Germany, France and Italy. Time to avoid these sell-ranked stocks?

ERYP : 11.10 (+0.36%)
TI : 6.96 (unch)
RACE : 140.00 (-1.77%)
BFRA : 12.99 (-0.08%)
DB : 12.03 (+0.08%)
SNY : 42.35 (+1.05%)
New England Journal of Medicine Publishes Final Results from Innovative Phase 2 Study Showing Vaccines Can Reduce Rate of Sustained TB Infections in Adolescents at High Risk

Aeras, a nonprofit organization dedicated to developing vaccines against tuberculosis (TB), today announced the publication of the full results from a Phase 2, randomized, controlled clinical trial of...

SAN : 5.43 (+0.37%)
SNY : 42.35 (+1.05%)
Sanofi denounces CADTH negative recommendation that could limit treatment options for Canadians with atopic dermatitis

Source: Sanofi (EURONEXT: SAN) (NYSE: SNY)

SAN : 5.43 (+0.37%)
SNY : 42.35 (+1.05%)
Regulus Stock Plunges on Cash Concerns Despite Restructuring

Regulus Therapeutics (RGLS) announces strategic and restructuring plans to extend cash runway. However, investors remain skeptical.

ALNY : 105.93 (-0.31%)
IONS : 46.50 (+1.44%)
RGLS : 0.28 (-3.45%)
SNY : 42.35 (+1.05%)
Sanofi's Blood Clotting Drug Gets Positive CHMP Opinion

Sanofi's (SNY) Cablivi for treating acquired thrombotic thrombocytopenic purpura nears approval with CHMP recommendation.

ALNY : 105.93 (-0.31%)
RHHBY : 29.4700 (+1.94%)
SNY : 42.35 (+1.05%)
BIIB : 358.71 (+0.17%)
Sanofi to further accelerate its scientific presence with the opening of a Global R&D Operations Hub in Chengdu, China

Sanofi (EURONEXT: SAN) (NYSE: SNY) is launching a Global R&D Operations Hub with a specialized focus on digitalization and big data analysis in Chengdu, Sichuan province, China. The new R&D operations...

SAN : 5.43 (+0.37%)
SNY : 42.35 (+1.05%)
Sanofi (SNY) Finalizes Deal for European Generic Unit Sale

Sanofi (SNY) finalizes sale of its European generic unit, Zentiva, for $2.2 billion.

CELG : 85.10 (-0.28%)
NVS : 82.27 (+1.82%)
GSK : 41.87 (+2.90%)
SNY : 42.35 (+1.05%)
Amgen's Repatha Reduces Bad Cholestrol in Type II Diabetes

Amgen's (AMGN) Repatha significantly reduces LDL-C and non-HDL-C in patients with type II diabetes and hypercholesterolemia or mixed dyslipidemia.

AGLE : 9.20 (-1.18%)
REGN : 367.11 (-0.17%)
AMGN : 190.49 (-0.66%)
SNY : 42.35 (+1.05%)
Sanofi presents results from the first head-to-head study comparing Toujeo® to insulin degludec

Sanofi (NYSE: SNY; EURONEXT: SAN) presented positive non-inferiority results of the BRIGHT study comparing its long-acting insulin Toujeo® to insulin degludec at the American Diabetes Association (ADA)...

SNY : 42.35 (+1.05%)
NICE Recommends Sanofi's New Treatment Dupixent(R) a- 1/4 (dupilumab) for Adults with Moderate to Severe Atopic Dermatitis in England[1]

GUILDFORD, England, June 22, 2018 /PRNewswire/ --

SNY : 42.35 (+1.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade SNY with:

Business Summary

Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing...

See More

Key Turning Points

2nd Resistance Point 42.88
1st Resistance Point 42.62
Last Price 42.35
1st Support Level 42.06
2nd Support Level 41.76

See More

52-Week High 50.65
Fibonacci 61.8% 45.60
Fibonacci 50% 44.04
Fibonacci 38.2% 42.48
Last Price 42.35
52-Week Low 37.43

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar